Rays Power Infra announced closure of INR 127 Crore Equity Capital Fund Raise - Union Minister Piyush Goyal Inaugurates Hunger Free World Initiative at Atal Bihari Vajpayee Kaushalya Vikas Kendra, Mumbai - CMR Green Technologies Limited Announced its Initial Public Offer (IPO) to open on June 3, 2026 At the Price Band of the Offer has been fixed at ₹ 182 to ₹ 192 per Equity Share - PM Modi's 12 Years: From Self-Reliant India to 'Make for the World' - Fadnavis, Chavan List Achievements - Sadbhavana Old Age Home needs ‘Mavtar’ The world’s largest ‘Vinubhai Bachubhai Nagrecha Campus’ Sadbhavana Old Age Home (Rajkot) requires childless, destitute, bedridden mavtar. Free admission will be given - Tata Realty and Salesforce Collaborate to Set New Benchmarks in AI-Led Customer Experience - Yami Gautam Dhar joins Surya Hospitals’ “The Amber Promise for Women’s Health” initiative during the launch of the Amber Wing at Santacruz Mumbai - Celebrating Innovation: HDFC SKY Shares Perspectives on India’s F&O Market Growth on National Technology Day - Rahul Shewale, Madhoo, Ashok Dhamankar and Mujtaba Aziz Naza Unveil the Latest Issue of ‘Society Interiors & Design’ Featuring Ar. Kavita & Ar. Soyuz Talib - Eugenix Hair Sciences celebrate 10 Years of Business Expansion Backed by 20,000+ Success Patients From a modest clinic in the Himalayan foothills to a name trusted across continents, Eugenix’s decade-long journey reflects a quiet revolution built on trust, innovation and patient-first care - VFS Global‑led consortium wins major citizen services contract to drive technology‑enabled transformation of 60 Model Sub‑Registrar Offices across Maharashtra

TECHNOLOGY



HDFC Bank partners with B2B pharma market place Retailio to launch co-branded credit cards, Aims to reach 1.4 lakh customers in initial phase

Mumbai, May 23, 2022 (GNI): HDFC Bank, India’s largest private sector bank and Retailio, India’s largest B2B pharma marketplace today announced the launch of a new range of co-branded credit cards. These B2B credit cards are…




Regrow Biosciences gets USFDA Nod for Phase II trials of ‘OSSGROW’ for Osteonecrosis in the US~OSSGROW is India’s first FDA (DCGI) approved product that has treated over 1000 patients across 200 hospitals in the country

Mumbai, 19 May 2022 (GNI): Regrow Biosciences, an Indian-centric global biotech company, is glad to announce a breakthrough achievement of getting a USFDA nod for conducting a phase II trial of its lead  product ‘OSSGROW,’…